Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide

The approval of abiraterone and enzalutamide for the treatment of advanced castration-resistant prostate cancer heralded a paradigm shift in the management of this disease. Nevertheless, new and improved treatments are needed since the disease remains incurable for the majority of these patients.

In this article, we review the biology of castration-resistant disease as well as emerging therapeutic compounds directed at the androgen receptor, including galeterone, VT-464, ARN-509, and ODM-201. Mechanisms of action, early clinical data, and ongoing clinical studies for these compounds are all reviewed. The need to find optimal sequencing and combination strategies as well as the need for predictive biomarkers of response to these agents is discussed.

Reference: Urol Oncol. 2015 Jul 7. pii: S1078-1439(15)00269-0.
DOI: 10.1016/j.urolonc.2015.05.025. [Epub ahead of print]

PubMed Abstract

Written by:
Bambury RM, Rathkopf DE
GU Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.